Disruption of Ferroptosis Inhibition and Immune Evasion with Tumor‐Activatable Prodrug for Boosted Photodynamic/Chemotherapy Eradication of Drug‐Resistant Tumors
Advanced Healthcare Materials · 2025-01 · 14 (2)
DOI: 10.1002/adhm.202403473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 12.11.2024. Verfasst von Tao Bi und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Traditional Chinese Medicine Clinical Research Base and Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Aff…. Hauptthemen laut MEDLINE: Doxorubicin, Drug Resistance, Neoplasm, Photochemotherapy, Ferroptosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Sichuan Province Science and Technology Support Program, Luzhou Science and Technology Bureau.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Breast cancer is a malignant tumor that threatens the life and health of women worldwide. As the first‐line chemotherapy drug for breast cancer, doxorubicin (DOX) can inhibit the synthesis of RNA and DNA, and it exhibits strong inhibitory activity against breast cancer. However, drug‐induced systemic toxicity and drug resistance can occur with DOX treatment. In this work, TSPO protein is identified as a promising target for overcoming drug resistance and we designed a novel BT‐DOX/PDP conjugate to solve these problems in drug chemotherapy. It is found that BT‐DOX/PDP can effectively downregulate TSPO1 protein and sensitize MCF‐7/Adr to DOX. Furthermore, due to its positive charge, BT‐DOX/PDP is readily loaded into puerarin (PUE), the resulting BT‐DOX/PDP@PUE exhibited minimal systemic toxicity but enhanced antitumor activity in animal models, as compared with BT‐DOX/PDP. This study demonstrates the advantages of combined chemotherapy and photodynamic therapy in overcoming drug resistance, which may be applied in the design of other photodynamic therapy‐based conjugates to enhance antitumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Traditional Chinese Medicine Clinical Research Base and Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical Unive…
- Institute of Integrated Chinese and Western Medicine, Southwest Medical University, Luzhou, Sichuan, 646000, China.
- State Key Laboratories for Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, 999078, China.
- Experimental Medicine Center, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, China.
ORCID-Profile: Zengjin Liu
Förderung
- China Postdoctoral Science Foundation
- Sichuan Province Science and Technology Support Program
- Luzhou Science and Technology Bureau
Zitieren
APA
Bi, T., Zhao, Q., Wang, T., Huang, R., Liu, B., Liu, X., Wang, Y., Sun, Q., Yang, Y., & Liu, Z. (2025). Disruption of Ferroptosis Inhibition and Immune Evasion with Tumor‐Activatable Prodrug for Boosted Photodynamic/Chemotherapy Eradication of Drug‐Resistant Tumors. Advanced Healthcare Materials, 14(2). https://doi.org/10.1002/adhm.202403473
Vancouver
Bi T, Zhao Q, Wang T, Huang R, Liu B, Liu X, et al. Disruption of Ferroptosis Inhibition and Immune Evasion with Tumor‐Activatable Prodrug for Boosted Photodynamic/Chemotherapy Eradication of Drug‐Resistant Tumors. Advanced Healthcare Materials. 2025;14(2). doi:10.1002/adhm.202403473
BibTeX
@article{Bi2025,
author = {Bi, Tao and Zhao, Qixin and Wang, Ting and Huang, Rui and Liu, Bangguo and Liu, Xinyue and Wang, Yihuan and Sun, Qin and Yang, Yingcheng and Liu, Zengjin},
title = {Disruption of Ferroptosis Inhibition and Immune Evasion with Tumor‐Activatable Prodrug for Boosted Photodynamic/Chemotherapy Eradication of Drug‐Resistant Tumors},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {2},
doi = {10.1002/adhm.202403473}
}
EUVIMED